Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer

Journal of Urology

Volumn 159, Issue 3, 1998, Pages 929-933

  Bauer, John J ^b   Connelly, Roger R ^b   Seterhenn, Isabell A ^b   Deausen, Joann ^b   Srivastava, Shiv ^b   Mcleod, David G ^b   Moul, Judd W ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NONE

Author keywords

Local; Neoplasm recurrence; Prostatectomy; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER STATISTICS; CANCER SURGERY; CAUCASIAN; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGRO; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RACE DIFFERENCE; RECURRENCE RISK; STATISTICAL ANALYSIS; STATISTICAL MODEL;

EID: 0031882519     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63773-X     Document Type: Article

References (25)

1. Wasson, J. H., Cushman, C. C., Bruskewitz, R. C., Littenberg, B., Mulley, A. G. and Wernberg, J. E.: A structured literature review of treatment for localized prostate cancer. Arch. Fam. Med., 2: 487, 1993.
2. Paulson, D. F., Moul, J. W., Robertson, J. E. and Walther, P. J.: Postoperative radiotherapy of the prostate for patients undergoing radical prostatectomy with positive margins, seminal vesicle involvement and/or penetration through the capsule. J. Urol., 143: 1178, 1990.
3. Hanks, G. E. and Dawson, A. K.: The role of external beam radiation therapy after prostatectomy for prostate cancer. Cancer, 58: 2406, 1986.
4. Gerber, G. S., Rukstalis, D. B. and Chodak, G. W.: Correlation of prostate specific antigen and tumor grade with nodal status in men with clinically localized prostate cancer. J. Urol., part 2, 149: 448A, abstract 940, 1993.
5. Kleer, E., Larson-Keller, J. J., Zinke, H. and Oesterling, J. E.: Ability of preoperative serum prostate-specific antigen value to predict pathological stage and DNA ploidy. Influence of clinical stage and tumor grade. Urology, 41: 207, 1993.
6. Partin, A. W., Yoo, J., Carter, H. B., Pearson, J. D., Chan, D. W., Epstein, J. I. and Walsh, P. C.: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol., 150: 110, 1993.
7. D'Amico, A. V., Whittington, R., Malkowicz, S. B., Schnall, M., Tomaszewski, J., Schultz, D., Kao, G., VanArsdalen, K. and Wein, A. A.: A multivariable analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer. Int. J. Rad. Oncol. Biol. Phys., 30: 293, 1994.
8. D'Amico, A. V., Whittington, R., Malkowicz, S. B., Schultz, D., Schnall, M., Tomaszewski, J. and Wein, A. A.: A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J. Urol., 154: 131, 1995.
9. Stamey, T. A., Freiha, F. S., McNeal, J. E., Redvine, E. A., Whitemore, A. S. and Schmid, H. P.: Localized prostate cancer: relationship of tumor volume to clinical significance for the treatment of prostate cancer. Cancer, suppl, 71: 933, 1993.
10. Lerner, S. E., Blute, M. L., Bergstralh, E. J., Bostwick, D. G., Eickholt, J. T. and Zinke, H.: Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J. Urol., 156: 137, 1996.
11. Partin, A. W., Piantadosi, S. and Marshall, F. F.: Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology, 45: 831, 1995.
12. Epstein, J. I., Pizov, G. and Walsh, P. C.: Correlation of pathological findings with progression after radical retropubic prostatectomy. Cancer, 71: 3582, 1993.
13. Norberg, M., Holberg, L., Wheeler, T. and Magnusson, A.: Five year follow-up after radical proatatectomy for localized prostate cancer: a study of the impact of different tumor variables on progression. Scand. J. Urol. Nephrol., 28: 391, 1994.
14. Ravery, V., Boccon-Gibod, L. A., Meulemans, A., Dauge-Geoffroy, M. C., Toublanc, M. and Boccon-Gibod, L.: Predictive value of pathological features for progression after radical prostatectomy. Eur. Urol., 26: 197, 1994.
15. Epstein, J. I., Carmichael, M. J., Pizov, G. and Walsh, P. C.: Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. J. Urol., 150: 135, 1993.
16. Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S. and Moul, J. W.: p53 Nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin. Can. Res., 1: 1295, 1995.
17. Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S. and Moul, J. W.: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer patients. J. Urol., 156: 1511, 1996.
18. Bettencourt, M. C., Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G. and Moul, J. W.: Ki-67 expression is an independent prognostic marker of recurrence in patients with organ confined prostate cancer after radical prostatectomy. J. Urol., 156: 1064, 1996.
19. Moul, J. W., Douglas, T. H., McCarthy, W. F. and McLeod, D. G.: Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J. Urol., 155: 1667, 1996.
20. Partin, A. W. and Oesterling, J. E.: The clinical usefulness of prostatic-specific antigen: update. J. Urol., 152: 1358, 1994.
21. Gleason, D. F.: Histological grading and clinical staging of prostate carcinoma. In: Urologic Pathology: The Prostate. Edited by M. Tannenbaum. Philadelphia: Lea & Febinger, pp. 171-197, 1977.
22. Mostofi, F. K., Sesterhenn, I. A. and Sobin, L. H.: Histological Typing of Prostate Tumors. Geneva: World Health Organization, 1980.
23. Obovi, M., Wheeler, T. M. and Scardino, P. T.: The American Joint Committee on Cancer and International Union Against Cancer. TNM classification of prostate cancer. Cancer, 73: 104, 1994.
24. Cox, D. R.: Regression models and life tables (with discussion). J. Roy. Stat. Soc. B., 34: 187, 1972.
25. Breslow, N. E.: Statistical methods for censored survival data. Envirn. Health Perspect., 32: 181, 1979.